Getinge 2022 Annual Report
Getinge 2022 Annual Report
Introduction
Strategy
Corporate Governance
Annual Report
Sustainability Report
Other information
Contents
Life Science
Life Science offers a comprehen-
sive range of equipment, technical
expertise and consultation in
research and production of
pharmaceuticals. The offering
includes:
• Solutions for the sterile transfer
of components, tools and liquids
•
•
Bioreactor systems for research
and production of, for example,
vaccines and drugs
Sterilizers, washer-disinfectors
and isolators
Customers' needs
Getinge partners with scientists and engineers to develop and
manufacture advanced pharmaceutical solutions. Focus is on
upstream bioprocessing, sterility and contamination prevention
to provide customized, efficient and compliant solutions for
customers and partners who are dedicated to prevent, mitigate
and cure diseases and to save lives.
Research and development
R&D focuses on the following product categories: washer-
disinfectors, steam sterilizers, isolators, sterile transfer and
bioprocessing systems. With this in mind, Getinge intends to further
develop a number of single-use bioreactors used for research
and production of biopharmaceuticals. In addition, Getinge is
committed to continue to strengthen its leading position in sterile
transfer. The offering for sterilization and disinfection for Life
Science customers is based on similar technology that exists in
the Surgical Workflows business area. However, the degree of
customized solutions is considerably higher in Life Science, and
a large degree of product development is conducted together with
the customers. This collaboration is generally comprehensive and
extends over a long time, presenting favorable opportunities to
create value for both parties.
Production sites
Life Science conducts production at a total of six production
sites in Sweden, France, Netherlands, Poland and the US. Intensive
activities have been carried out to meet the very high and sustained
demand in all product categories. The new production line of
DPTE®-BetaBags in Merrimack that was completed at the end of
2021 began to deliver sterile transfer solutions to customers in
2022. The production capacity of bioreactor systems also expanded
and, in France, the previously announced relocation of isolators from
the French production facility in Vendôme to Tournefeuille took
place. Life Science was the first of Getinge's business areas to reach
the status of being carbon neutral in its own production sites.
Sales and profitability
Organic sales increased somewhat year-on-year. This was
mainly related to the recovery of products and services in
which sales were prohibited in 2020-2021 as a result of
COVID-19. An unfavorable product mix and supply chain
disruptions had a negative impact on the operating margin
compared with the preceding year.
my
T
21
21View entire presentation